Global Next Generation Sequencing (NGS) Market Outlook: 2015-2020
Over the traditional technologies such as Microarray and Sanger Sequencing, the term Next Generation Sequencing was figured to portray the evolutionary breakthrough in DNA sequencing technologies to increase accuracy and speed, and reduce cost of sequencing. With different approach to sequencing, next generation sequencing has triggered numerous ground-breaking discoveries and ignited a revolution in genomic science. The adoption of rapidly evolving next generation sequencing technology has increased with support of government bodies like National Human Genome Research Institute (NHGRI) and Biotechnological and Biological Sciences Research Council (BBSRC, U.K.) and promotion by various research laboratories and academicians across the globe.
The global Next Generation Sequencing market is expected to grow at a CAGR of 21.3% from 2015 to 2020 to reach $8,599.5 million by 2020. This market is mainly driven by continuous innovation and developments in the market, promotion of NGS by research laboratories and academics, reduced cost of sequencing with the use of NGS, and rising support from various government bodies to promote use of NGS in research and development. As a result, various companies in the pharmaceutical industry have recognized the potential benefits of next generation sequencing as a research and development tool. This is evident from the recent major events such as agreement between Roche and Foundation Medicine to acquire a majority interest in Foundation Medicine for approximately $780 million, and various other agreements and investments from the companies like Genentech, Pfizer, and 10x Genomics. Moreover, an increase rate of cancer diseases, drastically reduced mass scale genetic testing costs, growing economy, and increasing genetic research and development activities in countries like India, Singapore, and China provide significant opportunities for the players to invest in this market. However, decrease in capital expenditure from academic institutions, high reliability on grants and funds from government, accuracy and standardization concern in diagnostic testing, and legal and ethical issues related to next generation sequencing hinders the growth of this market.
The North America held the largest share in the global NGS market followed by Europe and Asia-Pacific. The Asia-Pacific region provides significant opportunities for the NGS with China and India being the most populous countries in this region contributing to the increased demand for advanced sequencing facilities like NGS. As, the NGS market in Asia-Pacific region is expected to grow at a highest CAGR during the forecast period; many players in this market are focusing on strengthening their position in this region.
The research report titled “Global Next Generation Sequencing Market Outlook: 2015-2020” provides in-depth analysis of NGS market in four major geographies with country level analysis and emphasizes on the current market trends, market size, market share, recent developments, and forecast till 2020. The study offers a comprehensive analysis of NGS market with respect to its products and services, technology, methods, end-users, and applications.
The key players in the global NGS market are Illumina, Inc., Pacific Biosciences, Roche Holding AG, Thermo Fisher Scientific, Knome, Inc., Perkin Elmer, Inc., Qiagen N.V., Beijing Genomics Institute, Agilent Technologies, Inc., Partek Incorporated, Macrogen, Inc., GenoLogics Life Sciences Software, Inc., and Biomatters, Ltd.
Key questions answered in the report-
The global Next Generation Sequencing market is expected to grow at a CAGR of 21.3% from 2015 to 2020 to reach $8,599.5 million by 2020. This market is mainly driven by continuous innovation and developments in the market, promotion of NGS by research laboratories and academics, reduced cost of sequencing with the use of NGS, and rising support from various government bodies to promote use of NGS in research and development. As a result, various companies in the pharmaceutical industry have recognized the potential benefits of next generation sequencing as a research and development tool. This is evident from the recent major events such as agreement between Roche and Foundation Medicine to acquire a majority interest in Foundation Medicine for approximately $780 million, and various other agreements and investments from the companies like Genentech, Pfizer, and 10x Genomics. Moreover, an increase rate of cancer diseases, drastically reduced mass scale genetic testing costs, growing economy, and increasing genetic research and development activities in countries like India, Singapore, and China provide significant opportunities for the players to invest in this market. However, decrease in capital expenditure from academic institutions, high reliability on grants and funds from government, accuracy and standardization concern in diagnostic testing, and legal and ethical issues related to next generation sequencing hinders the growth of this market.
The North America held the largest share in the global NGS market followed by Europe and Asia-Pacific. The Asia-Pacific region provides significant opportunities for the NGS with China and India being the most populous countries in this region contributing to the increased demand for advanced sequencing facilities like NGS. As, the NGS market in Asia-Pacific region is expected to grow at a highest CAGR during the forecast period; many players in this market are focusing on strengthening their position in this region.
The research report titled “Global Next Generation Sequencing Market Outlook: 2015-2020” provides in-depth analysis of NGS market in four major geographies with country level analysis and emphasizes on the current market trends, market size, market share, recent developments, and forecast till 2020. The study offers a comprehensive analysis of NGS market with respect to its products and services, technology, methods, end-users, and applications.
The key players in the global NGS market are Illumina, Inc., Pacific Biosciences, Roche Holding AG, Thermo Fisher Scientific, Knome, Inc., Perkin Elmer, Inc., Qiagen N.V., Beijing Genomics Institute, Agilent Technologies, Inc., Partek Incorporated, Macrogen, Inc., GenoLogics Life Sciences Software, Inc., and Biomatters, Ltd.
Key questions answered in the report-
- Which are the high growth market segments in terms of NGS product and services, platforms, applications, end-users, methods, technology, regions, and countries?
- What is the historical market for NGS across the globe?
- What are the market forecasts and estimates from the period 2015-2020?
- What are the major drivers, restrains, threats, and opportunities in the global NGS market?
- What are the burning issues of the global NGS market?
- Who are the major players in the global NGS market and What share of the market do they hold?
- Who are the major players in various regions (North America, APAC, Europe) and What share of the market do they hold?
- What are the competitive landscapes and Who are the market leaders by sub-region in the global NGS market?
- What are the recent developments in the global NGS market?
- What are the different strategies adopted by the major players in the global NGS market?
- What are the geographical trends and high growth regions?
1 INTRODUCTION TO GLOBAL NGS MARKET
1.1 NGS Market Ecosystem
1.1.1 NGS Methods
1.1.2 NGS Products and Services
1.1.3 NGS Technology
1.1.4 NGS Application
1.1.5 NGS End-Users
1.2 Report Elucidation
1.3 Market Buzz and Foreground
1.4 Research Methodology
1.4.1 Secondary Research
1.4.2 Primary Research
1.4.3 Market Analytics
2 EXECUTIVE SUMMARY
3 MARKET INSIGHTS
3.1 Drivers
3.2 Restraints
3.3 Opportunities
3.4 Market Share Analysis
3.5 Market Trends
4 GLOBAL NGS- MARKET CRACKDOWN ($ VALUE ANALYSIS), BY METHODS
4.1 Genomics
4.1.1 Whole-Genome Sequencing
4.1.2 Exome Sequencing
4.1.3 De Novo Sequencing
4.1.4 Targeted Sequencing
4.2 Transcriptomics
4.2.1 Total RNA and mRNA Sequencing
4.2.2 Targeted RNA Sequencing
4.2.3 Small RNA and Noncoding RNA Sequencing
4.3 Epigenomics
4.3.1 Methylation Sequencing
4.3.2 ChIP Sequencing
4.3.3 Ribosome Profiling
5 GLOBAL NGS – MARKET CRACKDOWN ($ VALUE ANALYSIS), BY PRODUCTS AND SERVICES
5.1 NGS Reagents and accessories
5.1.1 Library Preparation
5.1.2 Template Preparation/Cluster generation
5.1.3 Sequencing
5.1.4 Others
5.2 Sequencing platforms
5.2.1 Illumina
5.2.2 Thermo Fisher Scientific (Life Technologies)
5.2.3 Roche
5.2.4 Pacific Biosciences
5.3 NGS Data analysis software and tools
5.4 Sequencing chips
5.5 NGS Services
5.6 Others
6 GLOBAL NGS – MARKET CRACKDOWN ($ VALUE ANALYSIS), BY TECHNOLOGY
6.1 Massively Parallel Signature Sequencing (MPSS)
6.2 Pyrosequencing
6.3 Sequencing by Synthesis (SBS)
6.4 Supported Oligonucleotide Ligation and Detection (SOLiD)
6.5 Ion Torrent Sequencing
6.6 True Single Molecule Sequencing (tSMS)
6.7 Single Molecule Real Time (SMRT) Sequencing
6.8 Other Sequencing Technologies
7 GLOBAL NGS – MARKET CRACKDOWN ($ VALUE ANALYSIS), BY APPLICATION
7.1 Drug Discovery
7.2 Genetic Screening
7.3 Diagnostics
7.4 Personalized Medicine
7.5 Agriculture And Animal Research
7.6 Others
8 GLOBAL NGS – MARKET CRACKDOWN ($ VALUE ANALYSIS), BY END-USERS
8.1 Academic and Research Organizations
8.2 Hospitals & Healthcare Institutions
8.3 Biopharma companies
8.4 Others
9 NGS – MARKET CRACKDOWN ($ VALUE ANALYSIS), BY GEOGRAPHY
9.1 North America
9.1.1 U.S.
9.1.2 Canada
9.2 Europe
9.2.1 Germany
9.2.2 France
9.2.3 U.K.
9.2.4 Italy
9.2.5 Spain
9.2.6 RoE
9.3 Asia-Pacific
9.3.1 Japan
9.3.2 China
9.3.3 India
9.3.4 RoAPAC
9.4 RoW
9.4.1 Latin America
9.4.2 Middle East & Africa
10 GLOBAL NGS MARKET- COMPETITIVE OUTLOOK
10.1 Agreements, Partnerships, Collaborations, Joint Ventures, and Expansions
10.2 Grants & Funds
10.3 Licensing
10.4 Mergers and Acquisitions
10.5 New Product Launches
10.6 Patents
10.7 Promotional & Marketing Activities
10.8 Other Developments
11 COMPETITIVE PROFILES – MAJOR PLAYERS
11.1 Illumina, Inc.
11.1.1 Company Overview
11.1.2 Financial Performance
11.1.3 Product & Services Portfolio
11.1.4 Growth Strategies
11.2 Thermo Fisher Scientific, Inc.
11.2.1 Company Overview
11.2.2 Financial Performance
11.2.3 Product & Services Portfolio
11.2.4 Growth Strategies
11.3 Roche Holding AG
11.3.1 Company Overview
11.3.2 Financial Performance
11.3.3 Product & Services Portfolio
11.3.4 Growth Strategies
11.4 Pacific Biosciences of California, Inc.
11.4.1 Company Overview
11.4.2 Financial Performance
11.4.3 Product & Services Portfolio
11.4.4 Growth Strategies
11.5 Oxford Nanopore Technologies Ltd.
11.5.1 Company Overview
11.5.2 Financial Performance
11.5.3 Product & Services Portfolio
11.5.4 Growth Strategies
11.6 Azco Biotech, Inc.
11.6.1 Company Overview
11.6.2 Financial Performance
11.6.3 Product & Services Portfolio
11.6.4 Growth Strategies
11.7 Affymetrix, Inc.
11.7.1 Company Overview
11.7.2 Financial Performance
11.7.3 Product & Services Portfolio
11.7.4 Growth Strategies
11.8 Agilent Technologies
11.8.1 Company Overview
11.8.2 Financial Performance
11.8.3 Product & Services Portfolio
11.8.4 Growth Strategies
11.9 BGI (Beijing Genomics Institute)
11.9.1 Company Overview
11.9.2 Financial Performance
11.9.3 Product & Services Portfolio
11.9.4 Growth Strategies
11.10 Gatc Biotech Ag
11.10.1 Company Overview
11.10.2 Financial Performance
11.10.3 Product & Services Portfolio
11.10.4 Growth Strategies
11.11 Beckman Coulter Genomics, Inc.
11.11.1 Company Overview
11.11.2 Financial Performance
11.11.3 Product & Services Portfolio
11.11.4 Growth Strategies
11.12 Macrogen Corporation
11.12.1 Company Overview
11.12.2 Financial Performance
11.12.3 Product & Services Portfolio
11.12.4 Growth Strategies
11.13 Perkin Elmer, Inc.
11.13.1 Company Overview
11.13.2 Financial Performance
11.13.3 Product & Services Portfolio
11.13.4 Growth Strategies
11.14 Qiagen N.V
11.14.1 Company Overview
11.14.2 Financial Performance
11.14.3 Product & Services Portfolio
11.14.4 Growth Strategies
11.15 DNASTAR, Inc
11.15.1 Company Overview
11.15.2 Financial Performance
11.15.3 Product & Services Portfolio
11.15.4 Growth Strategies
11.16 Knome, Inc
11.16.1 Company Overview
11.16.2 Financial Performance
11.16.3 Product & Services Portfolio
11.16.4 Growth Strategies
11.17 Partek Incorporated
11.17.1 Company Overview
11.17.2 Financial Performance
11.17.3 Product & Services Portfolio
11.17.4 Growth Strategies
11.18 Genomatix Software Gmbh
11.18.1 Company Overview
11.18.2 Financial Performance
11.18.3 Product & Services Portfolio
11.18.4 Growth Strategies
11.19 Biomatters Ltd
11.19.1 Company Overview
11.19.2 Financial Performance
11.19.3 Product & Services Portfolio
11.19.4 Growth Strategies
11.20 GenoLogics Life Sciences Software, Inc.
11.20.1 Company Overview
11.20.2 Financial Performance
11.20.3 Product & Services Portfolio
11.20.4 Growth Strategies
1.1 NGS Market Ecosystem
1.1.1 NGS Methods
1.1.2 NGS Products and Services
1.1.3 NGS Technology
1.1.4 NGS Application
1.1.5 NGS End-Users
1.2 Report Elucidation
1.3 Market Buzz and Foreground
1.4 Research Methodology
1.4.1 Secondary Research
1.4.2 Primary Research
1.4.3 Market Analytics
2 EXECUTIVE SUMMARY
3 MARKET INSIGHTS
3.1 Drivers
3.2 Restraints
3.3 Opportunities
3.4 Market Share Analysis
3.5 Market Trends
4 GLOBAL NGS- MARKET CRACKDOWN ($ VALUE ANALYSIS), BY METHODS
4.1 Genomics
4.1.1 Whole-Genome Sequencing
4.1.2 Exome Sequencing
4.1.3 De Novo Sequencing
4.1.4 Targeted Sequencing
4.2 Transcriptomics
4.2.1 Total RNA and mRNA Sequencing
4.2.2 Targeted RNA Sequencing
4.2.3 Small RNA and Noncoding RNA Sequencing
4.3 Epigenomics
4.3.1 Methylation Sequencing
4.3.2 ChIP Sequencing
4.3.3 Ribosome Profiling
5 GLOBAL NGS – MARKET CRACKDOWN ($ VALUE ANALYSIS), BY PRODUCTS AND SERVICES
5.1 NGS Reagents and accessories
5.1.1 Library Preparation
5.1.2 Template Preparation/Cluster generation
5.1.3 Sequencing
5.1.4 Others
5.2 Sequencing platforms
5.2.1 Illumina
5.2.2 Thermo Fisher Scientific (Life Technologies)
5.2.3 Roche
5.2.4 Pacific Biosciences
5.3 NGS Data analysis software and tools
5.4 Sequencing chips
5.5 NGS Services
5.6 Others
6 GLOBAL NGS – MARKET CRACKDOWN ($ VALUE ANALYSIS), BY TECHNOLOGY
6.1 Massively Parallel Signature Sequencing (MPSS)
6.2 Pyrosequencing
6.3 Sequencing by Synthesis (SBS)
6.4 Supported Oligonucleotide Ligation and Detection (SOLiD)
6.5 Ion Torrent Sequencing
6.6 True Single Molecule Sequencing (tSMS)
6.7 Single Molecule Real Time (SMRT) Sequencing
6.8 Other Sequencing Technologies
7 GLOBAL NGS – MARKET CRACKDOWN ($ VALUE ANALYSIS), BY APPLICATION
7.1 Drug Discovery
7.2 Genetic Screening
7.3 Diagnostics
7.4 Personalized Medicine
7.5 Agriculture And Animal Research
7.6 Others
8 GLOBAL NGS – MARKET CRACKDOWN ($ VALUE ANALYSIS), BY END-USERS
8.1 Academic and Research Organizations
8.2 Hospitals & Healthcare Institutions
8.3 Biopharma companies
8.4 Others
9 NGS – MARKET CRACKDOWN ($ VALUE ANALYSIS), BY GEOGRAPHY
9.1 North America
9.1.1 U.S.
9.1.2 Canada
9.2 Europe
9.2.1 Germany
9.2.2 France
9.2.3 U.K.
9.2.4 Italy
9.2.5 Spain
9.2.6 RoE
9.3 Asia-Pacific
9.3.1 Japan
9.3.2 China
9.3.3 India
9.3.4 RoAPAC
9.4 RoW
9.4.1 Latin America
9.4.2 Middle East & Africa
10 GLOBAL NGS MARKET- COMPETITIVE OUTLOOK
10.1 Agreements, Partnerships, Collaborations, Joint Ventures, and Expansions
10.2 Grants & Funds
10.3 Licensing
10.4 Mergers and Acquisitions
10.5 New Product Launches
10.6 Patents
10.7 Promotional & Marketing Activities
10.8 Other Developments
11 COMPETITIVE PROFILES – MAJOR PLAYERS
11.1 Illumina, Inc.
11.1.1 Company Overview
11.1.2 Financial Performance
11.1.3 Product & Services Portfolio
11.1.4 Growth Strategies
11.2 Thermo Fisher Scientific, Inc.
11.2.1 Company Overview
11.2.2 Financial Performance
11.2.3 Product & Services Portfolio
11.2.4 Growth Strategies
11.3 Roche Holding AG
11.3.1 Company Overview
11.3.2 Financial Performance
11.3.3 Product & Services Portfolio
11.3.4 Growth Strategies
11.4 Pacific Biosciences of California, Inc.
11.4.1 Company Overview
11.4.2 Financial Performance
11.4.3 Product & Services Portfolio
11.4.4 Growth Strategies
11.5 Oxford Nanopore Technologies Ltd.
11.5.1 Company Overview
11.5.2 Financial Performance
11.5.3 Product & Services Portfolio
11.5.4 Growth Strategies
11.6 Azco Biotech, Inc.
11.6.1 Company Overview
11.6.2 Financial Performance
11.6.3 Product & Services Portfolio
11.6.4 Growth Strategies
11.7 Affymetrix, Inc.
11.7.1 Company Overview
11.7.2 Financial Performance
11.7.3 Product & Services Portfolio
11.7.4 Growth Strategies
11.8 Agilent Technologies
11.8.1 Company Overview
11.8.2 Financial Performance
11.8.3 Product & Services Portfolio
11.8.4 Growth Strategies
11.9 BGI (Beijing Genomics Institute)
11.9.1 Company Overview
11.9.2 Financial Performance
11.9.3 Product & Services Portfolio
11.9.4 Growth Strategies
11.10 Gatc Biotech Ag
11.10.1 Company Overview
11.10.2 Financial Performance
11.10.3 Product & Services Portfolio
11.10.4 Growth Strategies
11.11 Beckman Coulter Genomics, Inc.
11.11.1 Company Overview
11.11.2 Financial Performance
11.11.3 Product & Services Portfolio
11.11.4 Growth Strategies
11.12 Macrogen Corporation
11.12.1 Company Overview
11.12.2 Financial Performance
11.12.3 Product & Services Portfolio
11.12.4 Growth Strategies
11.13 Perkin Elmer, Inc.
11.13.1 Company Overview
11.13.2 Financial Performance
11.13.3 Product & Services Portfolio
11.13.4 Growth Strategies
11.14 Qiagen N.V
11.14.1 Company Overview
11.14.2 Financial Performance
11.14.3 Product & Services Portfolio
11.14.4 Growth Strategies
11.15 DNASTAR, Inc
11.15.1 Company Overview
11.15.2 Financial Performance
11.15.3 Product & Services Portfolio
11.15.4 Growth Strategies
11.16 Knome, Inc
11.16.1 Company Overview
11.16.2 Financial Performance
11.16.3 Product & Services Portfolio
11.16.4 Growth Strategies
11.17 Partek Incorporated
11.17.1 Company Overview
11.17.2 Financial Performance
11.17.3 Product & Services Portfolio
11.17.4 Growth Strategies
11.18 Genomatix Software Gmbh
11.18.1 Company Overview
11.18.2 Financial Performance
11.18.3 Product & Services Portfolio
11.18.4 Growth Strategies
11.19 Biomatters Ltd
11.19.1 Company Overview
11.19.2 Financial Performance
11.19.3 Product & Services Portfolio
11.19.4 Growth Strategies
11.20 GenoLogics Life Sciences Software, Inc.
11.20.1 Company Overview
11.20.2 Financial Performance
11.20.3 Product & Services Portfolio
11.20.4 Growth Strategies
